Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from China’s NMPA for Melanoma Treatment

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...

April 02, 2025 | Wednesday | News
Yingli Pharma Receives FDA Clearance to Launch Phase 3 Trial for Linperlisib in Relapsed/Refractory PTCL

Shanghai Yingli Pharmaceutical Co., Ltd., a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune dis...

April 02, 2025 | Wednesday | News
Trump Administration Cuts 10,000 Federal Health Jobs, Sparking National Outcry

Massive Health Workforce Shake-Up: 10,000 Federal Health Agency Employees Face Layoffs Amid Budget Axes Trump administration has begun...

April 02, 2025 | Wednesday | News
FDA Approves Freeze-Dried Formulation of JYNNEOS® for Smallpox and Mpox Prevention

Bavarian Nordic A/S announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox and...

April 01, 2025 | Tuesday | News
Alnylam Presents New Data from HELIOS-B Trial at ACC.25, Highlighting Vutrisiran’s Impact on ATTR-CM Treatment

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced moderated poster presentations of new data from the landmark HELIOS-B...

March 31, 2025 | Monday | News
Novartis Announces FDA Approval for Expanded Use of Pluvicto® in mCRPC, Tripling Eligible Patient Access

Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with pro...

March 31, 2025 | Monday | News
FDA Approves CABOMETYX® for Treatment of Advanced Neuroendocrine Tumors in Adults and Pediatric Patients

 Exelixis, Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the tre...

March 28, 2025 | Friday | News
Sanofi’s mRNA Chlamydia Vaccine Candidate Receives Fast Track Designation from FDA

The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. ...

March 28, 2025 | Friday | News
Merck Reports Positive Phase 3 Results for Subcutaneous Pembrolizumab in Metastatic NSCLC

Merck known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the ...

March 28, 2025 | Friday | News
FDA Approves VYKAT XR for Treatment of Hyperphagia in Prader-Willi Syndrome

Soleno Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that the U.S. Food and D...

March 27, 2025 | Thursday | News
Theratechnologies Secures FDA Approval for EGRIFTA WR™, a More Convenient Formulation of Tesamorelin to Treat HIV-Associated Lipodystrophy

Theratechnologies Inc., a commercial-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved the Company&r...

March 26, 2025 | Wednesday | News
GSK Wins FDA Approval for Blujepa, First New Oral Antibiotic for UTIs in Nearly 30 Years

GSK plc announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg...

March 26, 2025 | Wednesday | News
FDA Fast-Tracks Tolebrutinib Review for Non-Relapsing Secondary Progressive MS Treatment

The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary pr...

March 26, 2025 | Wednesday | News
Clover Biopharmaceuticals Receives U.S. FDA IND Clearance for Phase I Revaccination Trial of SCB-1019 RSV Vaccine

Clover Biopharmaceuticals, Ltd, a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and ...

March 24, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close